Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Oncology Will Access Dana-Farber Technology

Premium

FRAMINGHAM, Mass.--Genzyme Molecular Oncology announced that it has entered into an agreement with the Dana-Farber Cancer Institute that will give the company an option to exclusively license novel fusion cell technology developed by researchers at Dana-Farber. Genzyme Molecular also said it has initiated funding at the institute.

Genzyme Molecular plans to combine fusion cell technology--the subject of a study published last month in the Proceedings of the National Academy of Sciences--with proprietary technologies such as Serial Analysis of Gene Expres sion, and Solid Phase Epitope Recovery, in an integrated antigen discovery program. Genzyme Molecular develops gene-based approaches to cancer therapy and diagnosis and employs an integrated approach to translate information gained through its genomics capabilities into gene therapy, small molecule therapeutics, and genetic diagnostics. Genzyme Molecular Oncology is a division of biotechnology company Genzyme and has its own common stock, not yet publicly traded.

Filed under

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.